On Thursday, Cenovus Energy Inc (USA) (NYSE:CVE)’s shares declined -1.88% to $16.20.
Cenovus Energy Inc (USA) (CVE) has agreed to purchase Canexus Corporation’s North American Terminal Operations (NATO), a crude-by-rail trans-loading facility, for $75 million, subject to adjustments. The acquisition is part of Cenovus’s strategy to create a portfolio of transportation options designed to maximize market access and capture global prices for its oil.
Located about 50 kilometres northeast of Edmonton in Bruderheim, Alberta, the terminal has planned value for Cenovus due to its existing pipeline connections to the Cold Lake and Access crude oil pipeline systems in addition to its links to the Canadian Pacific and Canadian National rail lines. Cenovus presently transports production volumes from its Foster Creek steam-assisted gravity drainage (SAGD) operation to Bruderheim on the Cold Lake pipeline. The terminal also has the ability to be expanded at a relatively low capital cost if changing market conditions make rail economics more attractive. Additionally, there is undeveloped land comprised of in the transaction that provides noteworthypotential for Cenovus as it evaluates a number of possible value-added projects.
Cenovus Energy Inc., an integrated oil company, develops, produces, and markets crude oil, natural gas liquids (NGLs), and natural gas in Canada with refining operations in the United States. The company’s Oil Sands segment engages in the development and production of bitumen assets at Foster Creek, Christina Lake, Narrows Lake, and the Athabasca natural gas assets, in addition to projects in the early stages of development, such as Grand Rapids and Telephone Lake. Its Conventional segment develops and produces conventional crude oil, NGLs, and natural gas in Alberta and Saskatchewan, counting the heavy oil assets at Pelican Lake.
STMicroelectronics NV (ADR) (NYSE:STM)’s showed no change to $8.56.
STMicroelectronics NV (ADR) (STM) declared the publication of the Company’s 2014 Sustainability Report. The Company’s eighteenth annual report contains comprehensive details of ST’s new sustainability strategy defined during 2014 and its performance while it illustrates how ST’s sustainability programs play a major role throughout the Company.
This report aligns with the Global Reporting Initiative’s G4[1], best-in-class reporting standards; ST was also one of the first companies to commit to the United Nations Global Compact[2] and the report represents the “Company’s Communication on Progress.
STMicroelectronics’ achievements in sustainability were recognized once again in 2014 with leading positions in various national and international sustainability ratings and indices. The company continued to be comprised of in the main Sustainability indices: Dow Jones Sustainability Europe where ST obtained a top score of 100 in product quality and recall administration, Euronext Vigeo, Carbon Disclosure Leadership Index in Italy, and FTSE4Good ethical index. These results highlight the many environmental sustainability actions the Company takes within its operations, in addition to its innovative sustainable products and services, which contributed to ST’s being comprised of, for the third successive year, in the Thomson Reuters annual ranking of the 100 most innovative companies in the world.
STMicroelectronics N.V. designs, develops, manufactures, and markets various semiconductor integrated circuits and discrete devices worldwide. The company offers a range of semiconductor products, counting discrete and standard commodity components, application-specific integrated circuits, full-custom devices and semi-custom devices, micro-electro-mechanical systems, microcontrollers, sensors, digital consumer products, imaging products, memory products, media application processors, and application-specific standard products for analog, digital, and mixed-signal applications, in addition to silicon chips and smartcards.
At the end of Thursday’s trade, RealPage, Inc. (NASDAQ:RP)‘s shares surged 1.25% to $18.64.
RealPage, Inc. (RP) declared it has leased a new corporate headquarters facility in Richardson, a suburb of Dallas, Texas. The new facility is intended to enhance seat capacity for long-term employee growth, consolidate remote facilities, improve partnership efficiency between offices around the world, and reduce the growth of facilities costs over time.
RealPage’s new headquarters will enhance total worldwide office space, but is predictable to reduce the company’s global facilities cost per seat by as much as 20 percent by 2017. The new lease will start in September 2016 and expire in 2028, with two, five-year options to renew. In conjunction with the expanded headquarters location, the company is reducing its real estate footprint in certain less efficient locations accumulated over time through acquisitions. Ultimately, the company anticipates that the headquarters move and the consolidation of remote facilities will result in lower average labor and occupancy cost per employee, in addition to raised total office square footage and seat capacity.
RealPage, Inc. provides demand software and software-enabled services for the rental housing and vacation rental industries in the United States. It offers property administration solutions, counting OneSite to serve the conventional multi-family, affordable properties, rural housing, privatized military housing, senior, student housing, and commercial sectors; and Propertyware for accounting, maintenance and work order administration, marketing spend administration, and portal services, in addition to screening, renter’s insurance, and payment solutions.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), ended its Thursday’s trading session with -2.67% loss, and closed at $120.46.
BioMarin Pharmaceutical Inc. (BMRN) declared that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present a company update at the Goldman Sachs 36th Annual Global Healthcare Conference on June 11th at 8:00a.m. PT. Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, www.BMRN.com. A replay of the presentation will be archived on the site for at least one week.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
